Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

This publication has 17 references indexed in Scilit:

• Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis.
  British Journal of Cancer, 1998
• Differential Expression of αv Integrins in K1735 Melanoma Cells
  Invasion and Metastasis, 1998
• Immunohistochemical analysis of integrin αvβ3 expression on tumor‐associated vessels of human carcinomas
  International Journal of Cancer, 1997
• Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.
  Proceedings of the National Academy of Sciences, 1996
• Definition of Two Angiogenic Pathways by Distinct α _v Integrins
  Science, 1995
• Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party
  Drug Information Journal, 1995
• Review: The Integrin α_vβ₃: Angiogenesis and Apoptosis
  Cell Adhesion and Communication, 1995
• Requirement of Vascular Integrin α _v β ₃ for Angiogenesis
  Science, 1994
• Integrins: Structure, Function, and Biological Properties
  Published by Elsevier ,1993
• Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor.
  Proceedings of the National Academy of Sciences, 1987